Antibiotic
GSK, Spero Report Major Phase 3 Win for UTI Antibiotic; Spero’s Stock Surges
GSK; Spero Therapeutics; tebipenem HBr; Phase 3 trial; UTI antibiotic; complicated urinary tract infection; PIVOT-PO trial; stock surge; clinical trial results; FDA submission
FDA Advisory Committee Narrowly Votes Against UroGen’s Bladder Cancer Drug, Calls for Further Studies
FDA; UroGen Pharma; UGN-102; bladder cancer; Oncologic Drugs Advisory Committee; mitomycin; RCT; non–muscle invasive bladder cancer; clinical trials
Vaccine-probiotic combo prevents, clears bacterial gut infections in mice in antibiotic alternative test
Antibiotics, Probiotics, House mice, Immune response, Vaccines
FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections
Emblaveo, aztreonam, avibactam, antibiotic resistance, Gram-negative bacteria, intra-abdominal infections, AbbVie
NHS England Approves Groundbreaking CRISPR Gene Therapy for Sickle Cell Disease
Casgevy, exagamglogene autotemcel, CRISPR gene therapy, sickle cell disease, NHS England, Vertex Pharmaceuticals, NICE approval
Revance Therapeutics Faces Competing Buyout Offers: Teoxane SA Outbids Crown Laboratories
Revance Therapeutics, Teoxane SA, Crown Laboratories, buyout offers, merger agreement, biotechnology, skincare industry
NICE Rejects Enhertu for NHS Use Due to Pricing Stalemate with AstraZeneca and Daiichi Sankyo
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, breast cancer, pricing stalemate, NHS, England
Journey Medical’s Emrosi Receives FDA Approval, Setting New Standard for Rosacea Treatment
Rosacea treatment, Emrosi, FDA approval, Minocycline hydrochloride, Journey Medical Corporation, Dermatological conditions, New standard of care
Iterum Therapeutics Secures FDA Approval for Orlynvah, Breaking Two-Decade Drought in New UTI Treatments
Iterum Therapeutics, FDA Approval, Orlynvah, Uncomplicated Urinary Tract Infections (uUTIs), Sulopenem Etzadroxil and Probenecid, Oral Penem
NICE Rejects Alzheimer’s Drug Kisunla Despite UK Regulatory Approval
NICE, Alzheimer’s disease, donanemab, Kisunla, Eli Lilly, MHRA, NHS, cost-effectiveness